No abstract

Brightness and color are two basic visual features integrated by the human visual system (HVS) to gain a better understanding of color natural scenes. Aiming to combine these two cues to maximize the reliability of boundary detection in natural scenes, we propose a new framework based on the color-opponent mechanisms of a certain type of color-sensitive double-opponent (DO) cells in the primary visual cortex (V1) of HVS. This type of DO cells has oriented receptive field with both chromatically and spatially opponent structure. The proposed framework is a feedforward hierarchical model, which has direct counterpart to the color-opponent mechanisms involved in from the retina to V1. In addition, we employ the spatial sparseness constraint (SSC) of neural responses to further suppress the unwanted edges of texture elements. Experimental results show that the DO cells we modeled can flexibly capture both the structured chromatic and achromatic boundaries of salient objects in complex scenes when the cone inputs to DO cells are unbalanced. Meanwhile, the SSC operator further improves the performance by suppressing redundant texture edges. With competitive contour detection accuracy, the proposed model has the additional advantage of quite simple implementation with low computational cost.

Color information plays an important role in better understanding of natural scenes by at least facilitating discriminating boundaries of objects or areas. In this study, we propose a new framework for boundary detection in complex natural scenes based on the color-opponent mechanisms of the visual system. The red-green and blue-yellow color opponent channels in the human visual system are regarded as the building blocks for various color perception tasks such as boundary detection. The proposed framework is a feedforward hierarchical model, which has direct counterpart to the color-opponent mechanisms involved in from the retina to the primary visual cortex (V1). Results show that our simple framework has excellent ability to flexibly capture both the structured chromatic and achromatic boundaries in complex scenes.

Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with deletion of chromosome 5q and other hematological malignancies. Recent studies showed that IMiDs bind to CRBN, a substrate receptor of CRL4 E3 ligase, to induce the ubiquitination and degradation of IKZF1 and IKZF3 in multiple myeloma cells, contributing to their anti-myeloma activity. Similarly, lenalidomide exerts therapeutic efficacy via inducing ubiquitination and degradation of CK1α in MDS with deletion of chromosome 5q. Recently, novel thalidomide analogs have been designed for better clinical efficacy, including CC-122, CC-220 and CC-885. Moreover, a number of neo-substrates of IMiDs have been discovered. Proteolysis-targeting chimeras (PROTACs) as a class of bi-functional molecules are increasingly used as a strategy to target otherwise intractable cellular protein. PROTACs appear to have broad implications for novel therapeutics. In this review, we summarized new generation of immunomodulatory compounds, their potential neo-substrates, and new strategies for the design of novel PROTAC drugs.